| 0.7212 0.021 (2.97%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.05 | 1-year : | 1.22 |
| Resists | First : | 0.9 | Second : | 1.04 |
| Pivot price | 0.85 |
|||
| Supports | First : | 0.67 | Second : | 0.55 |
| MAs | MA(5) : | 0.75 |
MA(20) : | 0.84 |
| MA(100) : | 0.85 |
MA(250) : | 1.46 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 12.7 |
| RSI | RSI(14): 40.5  |
|||
| 52-week | High : | 3.06 | Low : | 0.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IVVD ] has closed above bottom band by 12.8%. Bollinger Bands are 3.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.74 - 0.74 | 0.74 - 0.75 |
| Low: | 0.68 - 0.69 | 0.69 - 0.69 |
| Close: | 0.71 - 0.72 | 0.72 - 0.73 |
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Thu, 08 Oct 2026
Invivyd Slides As Insider Purchases Lose Another US$89k - Simply Wall Street
Mon, 05 Oct 2026
Six new hires receive options to buy 157,500 Invivyd shares - Stock Titan
Thu, 01 Oct 2026
Lobbying Update: $60,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Tue, 29 Sep 2026
Invivyd delays trial data for COVID drug (IVVD:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 295 (M) |
| Shares Float | 208 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 86.9 (%) |
| Shares Short | 33,860 (K) |
| Shares Short P.Month | 29,790 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.61 |
| Profit Margin | -183.9 % |
| Operating Margin | -320.8 % |
| Return on Assets (ttm) | -45.7 % |
| Return on Equity (ttm) | -95.9 % |
| Qtrly Rev. Growth | 21.2 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -108 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -2.19 |
| PEG Ratio | 0 |
| Price to Book value | 1.18 |
| Price to Sales | 3.64 |
| Price to Cash Flow | -1.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|